1 / 32

Disclosures

Two-Year Follow-up from a Prospective, Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare-Metal Stents in STEMI Gregg W. Stone MD For the HORIZONS-AMI Investigators. Disclosures. Gregg W. Stone MD

deacon-cline
Download Presentation

Disclosures

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Two-Year Follow-up from a Prospective, Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare-Metal Stents in STEMI Gregg W. Stone MD For the HORIZONS-AMI Investigators

  2. Disclosures • Gregg W. Stone MD • Advisory Board for Boston Scientific and Abbott Vascular • Research support from The Medicines Company

  3. Background At 1-year in the 2x2 factorial prospective, randomized HORIZONS-AMI trial: Bivalirudin alone compared to heparin plus GPIIb/IIIa inhibitors resulted in comparable rates of MI and stent thrombosis, with significantly reduced rates of major bleeding and mortality (all-cause and cardiac) TAXUS PES compared to EXPRESS BMS reduced clinical and angiographic restenosis, with comparable rates of death, reinfarction and stent thrombosis Whether these findings are sustained at 2 years has not been reported

  4. Harmonizing Outcomes with Revascularization and Stents in AMI 3602 pts with STEMI with symptom onset ≤12 hours Aspirin, thienopyridine UFH + GP IIb/IIIa inhibitor (abciximab or eptifibatide) Bivalirudin monotherapy (± provisional GP IIb/IIIa) Emergent angiography, followed by triage to… R 1:1 R 3:1 CABG – – Primary PCI Medical Rx 3006 pts eligible for stent randomization Paclitaxel-eluting TAXUS stent Bare metal EXPRESS stent Clinical FU at 30 days, 6 months, 1 year, and then yearly through 5 years; angio FU at 13 months

  5. Harmonizing Outcomes with Revascularization and Stents in AMI 3602 pts with STEMI R 1:1 UFH + GP IIb/IIIa N=1802 Bivalirudin N=1800 Randomized • • • Not true MI* • • • 30 29 N=1772 N=1771 1-Year FU Eligible • • • Withdrew • • • • • • Lost to FU • • • 26 13 22 19 N=1733 (97.8%) N=1730 (97.7%) 1-Year FU • • • Withdrew • • • • • • Lost to FU • • • 13 48 12 25 N=1672 (94.4%) N=1693 (95.6%) 2-Year FU * Biomarkers WNL and no DS >50% by core lab determination (30 day FU only)

  6. Pharmacology Randomization: Aspirin and Thienopyridine Use Regular* aspirin use (%) Regular* thieno. use (%) 98.1% 97.3% 97.0% 96.1% 95.2% 93.7% 93.3% 87.7% 97.1% 96.7% 96.3% 92.9% 92.7% 95.2% 95.7% 87.1% 67.8% 65.6% Antiplatelet agent use (%) 35.8% All P = NS All P = NS 32.7% Bivalirudin alone (n=1800) *Taken >50% of days since last visit Heparin + GPIIb/IIIa (n=1802)

  7. Two-Year Major Bleeding (non-CABG)* Bivalirudin alone (n=1800) 12 Heparin + GPIIb/IIIa (n=1802) 10 9.6% 8 6.4% Major Bleeding (%) 6 4 HR [95%CI]= 0.64 [0.51, 0.81] 2 p<0.001 0 0 3 6 9 12 15 18 21 24 Months Number at risk 1800 1603 1571 1540 1290 Bivalirudin alone 1802 1535 1505 1453 1218 Heparin+GPIIb/IIIa *Intracranial intraocular, retroperitoneal, access site bleed requiring intervention/surgery, hematoma ≥5 cm, hgb ↓ ≥3g/dL with or ≥4g/dL w/o overt source; reoperation for bleeding; or blood product transfusion

  8. Two-Year Major Adverse CV Events* Bivalirudin alone (n=1800) 24 Heparin + GPIIb/IIIa (n=1802) 18.8% 20 18.7% 16 MACE (%) 12 HR [95%CI]= 1.00 [0.86, 1.17] 8 p= 0.99 4 0 0 3 6 9 12 15 18 21 24 Months Number at risk Bivalirudin alone 1800 1584 1513 1400 1159 1802 1577 1518 1399 1142 Heparin+GPIIb/IIIa • *MACE = All cause death, reinfarction, ischemic TVR or stroke

  9. Two-Year All-Cause Mortality Bivalirudin alone (n=1800) 8 Heparin + GPIIb/IIIa (n=1802) 7 6.1% 6 5 4.6% 3.1% All-Cause Mortality (%) 4 HR [95%CI]= 3 0.75 [0.56, 1.00] 2 2.1% p= 0.049 1 month P=0.049 1 0 0 3 6 9 12 15 18 21 24 Months Number at risk 1800 1690 1658 1627 1359 Bivalirudin alone 1802 1669 1637 1579 1324 Heparin+GPIIb/IIIa

  10. Two-Year Mortality: Cardiac and Non Cardiac Heparin + GPIIb/IIIa (n=1802) Bivalirudin alone (n=1800) Cardiac Mortality Non Cardiac Mortality 5 5 4.2% 4 4 HR [95% CI]= 1.10 [0.69, 1.76] 3 3 p= 0.69 Mortality (%) 2.5% 2.2% 2.0% 2 2 HR [95% CI]= 0.59 [0.41, 0.86] 1 1 p= 0.005 0 0 0 3 6 9 12 15 18 21 24 0 3 6 9 12 15 18 21 24 Months Months Number at risk Bivalirudin alone 1800 1690 1658 1627 1359 1800 1690 1658 1359 1627 Heparin+GPIIb/IIIa 1802 1669 1637 1579 1324 1802 1669 1637 1324 1579

  11. Two-Year Reinfarction Bivalirudin alone (n=1800) 10 Heparin + GPIIb/IIIa (n=1802) 9 8 6.9% 7 6 5.1% Reinfarction (%) 5 4 HR [95%CI]= 3 0.75 [0.56, 0.98] 2 p= 0.038 1 0 0 3 6 9 12 15 18 21 24 Months Number at risk 1800 1644 1603 1554 1298 Bivalirudin alone 1802 1621 1576 1500 1244 Heparin+GPIIb/IIIa

  12. Two-Year Death or Reinfarction Bivalirudin alone (n=1800) 15 Heparin + GPIIb/IIIa (n=1802) 12.0% 12 9.1% 9 Death or reinfarction (%) 6 HR [95%CI]= 0.75 [0.61, 0.93] 3 p= 0.007 0 0 3 6 9 12 15 18 21 24 Months Number at risk 1800 1644 1603 1554 1298 Bivalirudin alone 1802 1621 1576 1500 1244 Heparin+GPIIb/IIIa

  13. Two-Year MACE Components* *All Kaplan-Meier estimates, CEC adjudicated

  14. Adverse Events Between 30 Days and 2-Years *Kaplan-Meier estimates, landmark analysis, CEC adjudicated

  15. 2-Year Stent Thrombosis(ARC Definite/Probable) Bivalirudin alone (n=1800) Heparin + GPIIb/IIIa (n=1802) 6 5 4.6% 4.3% 4 Stent Thrombosis (%) 3 HR [95%CI]= 0.94 [0.67, 1.32] 2 p= 0.73 1 0 0 3 6 9 12 15 18 21 24 Months Number at risk Bivalirudin alone 1611 1509 1475 1444 1206 Heparin+GPIIb/IIIa 1591 1482 1449 1386 1153

  16. 2-Year Stent Thrombosis* (N=3,202) *All Kaplan-Meier estimates; all CEC adjudicated

  17. Harmonizing Outcomes with Revascularization and Stents in AMI UFH + GPI (n=1802) Bivalirudin (n=1800) 3602 pts with STEMI R 1:1 Primary Medical Rx 193 Primary CABG 62 Deferred PCI 2 Index PCI, not eligible - PTCA only 119 - Stented 220 3006 pts eligible for stent rand. 93.1% of all stented pts were randomized R 3:1 TAXUS DES N=2257 EXPRESS BMS N=749 Randomized • • • Withdrew • • • • • • Lost to FU • • • 18 16 7 13 1 year FU N=2223 (98.5%) N=729 (97.3%) 13 month angiographic FU 942 307 12 54 • • • Withdrew • • • • • • Lost to FU • • • 6 8 2 year FU N=2157 (95.6%) N=715 (95.5%)

  18. TAXUS DES (n=2257) Stent Randomization: Aspirin and Thienopyridine Use EXPRESS BMS (n=749) Regular* aspirin use (%) Regular* thieno. use (%) 99.4% 99.1% 98.7% 98.5% 98.3% 97.5% 97.5% 94.6% 98.9% 97.8% 98.6% 98.3% 97.5% 97.1% 96.2% 72.8% 87.5% P<0.001 Antiplatelet agent use (%) 63.8% All P=NS P<0.001 36.8% 30.7% P=0.004 *Taken >50% of days since last visit

  19. Primary Efficacy Endpoint: Ischemic TLR TAXUS DES (n=2257) 15 EXPRESS BMS (n=749) 12 11.6% 9 Ischemic TLR (%) 6.8% 6 HR [95%CI]= 0.58 [0.44, 0.76] 3 P<0.001 0 0 3 6 9 12 15 18 21 24 Months Number at risk TAXUS DES 2257 2105 2041 1949 1618 EXPRESS BMS 749 677 654 611 507

  20. Primary Efficacy Endpoint: Ischemic TLR TAXUS DES (n=2257) 15 EXPRESS BMS (n=749) 12 11.6% 13 mo angio FU 9 Ischemic TLR (%) 6.8% 6 HR [95%CI]= 0.58 [0.44, 0.76] 3 1-yr HR [95%CI]= P<0.001 0.60 [0.43, 0.84] p= 0.002 0 0 3 6 9 12 15 18 21 24 Months Number at risk TAXUS DES 2257 2105 2041 1949 1618 EXPRESS BMS 749 677 654 611 507

  21. Secondary Efficacy Endpoint: Ischemic TVR TAXUS DES (n=2257) 15 EXPRESS BMS (n=749) 13.3% 12 8.9% 9 Ischemic TVR (%) 6 HR [95%CI]= 0.66 [0.51, 0.84] 1-yr HR [95%CI]= P<0.001 3 0.66 [0.49, 0.89] p= 0.007 0 0 3 6 9 12 15 18 21 24 Months Number at risk TAXUS DES 2257 2085 2016 1912 1587 EXPRESS BMS 749 671 646 600 498

  22. Primary Safety Endpoint: Safety MACE* TAXUS DES (n=2257) 16 EXPRESS BMS (n=749) 14 11.2% 12 11.0% 10 Safety MACE (%) 8 HR [95%CI]= 6 0.98 [0.77, 1.26] p= 0.90 4 2 0 0 3 6 9 12 15 18 21 24 Months Number at risk TAXUS DES 2257 2094 2035 1958 1619 EXPRESS BMS 749 684 667 645 530 * Safety MACE = death, reinfarction, stroke, or stent thrombosis

  23. Two-Year All-Cause Mortality TAXUS DES (n=2257) 8 EXPRESS BMS (n=749) 7 6 5.2% 5 4.3% All-Cause Mortality (%) 4 3 HR [95%CI]= 0.83 [0.57, 1.20] 2 p= 0.32 1 0 0 3 6 9 12 15 18 21 24 Months Number at risk TAXUS DES 2257 2170 2134 2083 1742 EXPRESS BMS 749 714 700 680 566

  24. Two-Year Cardiac Mortality TAXUS DES (n=2257) 6 EXPRESS BMS (n=749) 5 4 3.3% Cardiac Mortality (%) 3 2.7% 2 HR [95%CI]= 0.83 [0.52, 1.33] 1 p= 0.43 0 0 0 3 3 6 6 9 9 12 12 15 15 18 18 21 21 24 24 Months Number at risk TAXUS DES 2257 2170 2134 2083 1742 EXPRESS BMS 749 714 700 680 566

  25. Two-Year Reinfarction TAXUS DES (n=2257) 10 EXPRESS BMS (n=749) 9 8 7 6.1% 6 5.7% Reinfarction (%) 5 4 HR [95%CI]= 3 0.92 [0.65, 1.30] p= 0.64 2 1 0 0 0 3 3 6 6 9 9 12 12 15 15 18 18 21 21 24 24 Months Number at risk TAXUS DES 2257 2118 2062 1998 1645 EXPRESS BMS 749 690 674 651 538

  26. Two-Year Stent Thrombosis(ARC Definite or Probable) TAXUS DES (n=2257) EXPRESS BMS (n=749) 6 5 4.1% 4.1% 4 Stent Thrombosis (%) 3 HR [95%CI]= 1.00 [0.66, 1.51] 2 p= 0.99 1 0 0 3 6 9 12 15 18 21 24 Months Number at risk TAXUS DES 2238 2108 2061 1998 1661 EXPRESS BMS 744 696 681 661 547

  27. 2-Year Stent Thrombosis* *All Kaplan-Meier estimates; all CEC adjudicated

  28. Two Year Composite Safety Endpoints* *Kaplan-Meier estimates

  29. Adverse Events Between 1 and 2 Years* *Kaplan-Meier estimates

  30. Two-Year Mortality (All-Cause) Heparin + GPI / TAXUS (n=1111) Heparin + GPI / EXPRESS (n=368) 8 Bivalirudin / TAXUS (n=1146) Bivalirudin / EXPRESS (n=381) 7 6.1% 6 5 4.7% 4.3% All-Cause Mortality (%) 4 3.8% 3 2 Pint = 0.73 1 0 0 3 6 9 12 15 18 21 24 Months

  31. Conclusions: Pharmacology Randomization • In this large-scale, prospective, randomized trial of pts with STEMI undergoing primary PCI, at 2 years initial treatment with bivalirudin alone compared to heparin plus GPIIb/IIIa inhibitors resulted in: • A significant 36% reduction in major bleeding and a significant 25% reduction in reinfarction, with comparable rates of stent thrombosis, TVR and stroke • A significant 41% reduction in cardiac mortality and a 25% reduction in all-cause mortality, the latter representing 15 lives saved per 1000 patients treated with bivalirudin (NNT = 67 to save 1 life)

  32. Conclusions: Stent Randomization • Among pts with STEMI undergoing primary PCI, at 2 years the implantation of TAXUS paclitaxel-eluting EXPRESS stents compared to EXPRESS bare metal stents resulted in: • Significant 42% and 34% reductions in ischemic TLR and TVR respectively, with no evidence of late catch-up • Comparable rates of all-cause and cardiac mortality, reinfarction and stent thrombosis, with no safety concerns apparent • TLR, TVR and mortality were reduced between 1 and 2 years in pts treated with TAXUS EXPRESS compared to EXPRESS BMS, observations that should be considered hypothesis generating given their borderline significance and possible influence of routine angiographic follow-up

More Related